MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1586/17512433.2016.1145053

Медицинская библиотека · Expert review of clinical pharmacology · 2016

Alternatives for reducing relapse rate when switching from natalizumab to fingolimod in multiple sclerosis.

Fragoso Yara Dadalti, Adoni Tarso, Alves-Leon Soniza Vieira, Apostolos-Pereira Samira Luisa, Araujo Yuna Ribeiro de, Becker Jefferson, Brooks Joseph Bruno Bidin, Correa Eber Castro, Damasceno Alfredo, Damasceno Carlos Augusto de Albuquerque, Ferreira Maria Lucia B, Gama Paulo Diniz da, Gama Rodrigo Assad Diniz da, Gomes Sidney, Goncalves Marcus Vinicius Magno, Grzesiuk Anderson Kuntz, Machado Suzana Costa Nunes, Matta Andre Palma da Cunha, Mendes Maria Fernanda, Ribeiro Taysa Alexandrino Goncalves Jube, Rocha Cristiane Franklin da, Ruocco Heloisa Helena, Sato Henry, Simm Renata Faria, Tauil Carlos Bernardo, Vasconcelos Claudia Cristina Ferreira, Vieira Vera Lucia Ferreira

СтатьяПеревод в очереди

Аннотация

Natalizumab is a therapeutic option for treating multiple sclerosis (MS) and is particularly efficacious for patients with highly active disease. A long washout period has been recommended between withdrawal of natalizumab and start of fingolimod (another option for treating MS). This long washout period has been associated with a significant increase in MS activity. In the present study, a group of 96 patients who were switched from natalizumab to fingolimod had short washout periods between drugs, or monthly corticosteroid pulse therapy if longer washout periods were recommended. This therapeutic approach led to the lowest reported relapse rate so far, among patients with MS switching from natalizumab to fingolimod (8.3%). No complications from short withdrawal were observed in this group of patients.

Для цитирования: Fragoso Yara Dadalti, Adoni Tarso, Alves-Leon Soniza Vieira, Apostolos-Pereira Samira Luisa, Araujo Yuna Ribeiro de, Becker Jefferson, Brooks Joseph Bruno Bidin, Correa Eber Castro, Damasceno Alfredo, Damasceno Carlos Augusto de Albuquerque, Ferreira Maria Lucia B, Gama Paulo Diniz da, Gama Rodrigo Assad Diniz da, Gomes Sidney, Goncalves Marcus Vinicius Magno, Grzesiuk Anderson Kuntz, Machado Suzana Costa Nunes, Matta Andre Palma da Cunha, Mendes Maria Fernanda, Ribeiro Taysa Alexandrino Goncalves Jube, Rocha Cristiane Franklin da, Ruocco Heloisa Helena, Sato Henry, Simm Renata Faria, Tauil Carlos Bernardo, Vasconcelos Claudia Cristina Ferreira, Vieira Vera Lucia Ferreira. Alternatives for reducing relapse rate when switching from natalizumab to fingolimod in multiple sclerosis.. Expert review of clinical pharmacology. 2016. DOI: 10.1586/17512433.2016.1145053.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.